Published in Drug Week, September 10th, 2004
Sales of Colazal (balsalazide disodium) capsules 750 mg generated product revenue of $18.9 million for the second quarter of 2004 compared to $12.9 million for the second quarter of 2003. This represents an increase of 46% over the prior year period. Colazal revenue for the first 6 months of 2004 was $38.3 million, an increase of 56%, compared to $24.5 million for the first 6 months of 2003.
Total product revenue, derived primarily from sales of Colazal, was $19.4 million for the second quarter and $39.3 million for the first half...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.